EUCTR2019-002120-32-BE进行中（未招募）1 期
A Single Arm, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Paediatric Subjects 3 Months to < 18 Years of Age with Suspected or Confirmed Aerobic Gram-negative Bacterial Infections - PEDI-CEFI
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject’s parent(s) or legally authorized representative (LAR) provides written informed consent in accordance with regional and country-specific laws and regulations
- •2.Subject provides written informed assent, when feasible (age of assent to be determined by institutional review boards/independent ethics committees [IRB's/IEC's] or be consistent with local legal requirements)
- •3.Hospitalized subject is 3 months to < 18 years of age at the time written informed consent/assent is obtained for the single-dose phase.
- •Hospitalized subject is 3 months to < 12 years of age at the time written
- •informed consent/assent is obtained for the multiple-dose phase.
- •Premature babies will not be restricted, but the subject must have an
- •adjusted or postnatal age of 3 months.
- •4.Subject has a suspected or confirmed infection (including but not limited to cUTI, cIAI, pneumonia [including HAP/VAP], sepsis, or BSI) that requires hospitalization for treatment with IV antibiotics
- •5.If subject is a female of childbearing potential and has reached menarche or Tanner stage 3, subject agrees to use barrier contraception (including condom, diaphragm, or cervical cap) with spermicide or agrees to use a highly effective method of contraception (including contraceptive implant, injectable contraceptive, combination oral contraceptive, or an intrauterine [IUD] contraceptive device) from screening up to 28 days after administration of the last dose of cefiderocol
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 64
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subject has a documented history of any hypersensitivity or allergic reaction to any ß-lactam antibiotic (Note: for ß-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment)
- •2.Multiple-dose only: Subject has an infection caused only by a confirmed Gram-positive pathogen
- •3.Subject has a suspected or confirmed central nervous system (CNS) infection (eg, meningitis, brain abscess, shunt infection) or osteomyelitis (which would require prolonged antibiotic therapy)
- •4.Subject has cystic fibrosis
- •5.Single-dose phase: Subject has moderate or severe renal impairment based on estimated glomerular filtration rate (eGFR) (based on modified Bedside Schwartz equation [2009]) of < 60 mL/min/1.73 m2 at Screening
- •Multiple-dose phase: Subject has an eGFR (based on modified Bedside Schwartz equation [2009]) of < 15 mL/min/1.73 m2 at Screening
- •6.Subject has end-stage renal disease (ESRD), is on hemodialysis (HD), or receiving continuous venovenous hemofiltration (CVVH)
- •7.Subject has experienced septic shock in the prior month or is in shock at the time of Screening
- •8.Subject has severe neutropenia or is severely immunocompromised
- •9.Subject has multiorgan failure
- •10.Subjects has a life expectancy of < 30 days due to severity of a concurrent illness
- •11.Subject is a female who has a positive pregnancy test at Screening
- •12.Subject is a female who is breastfeeding
- •13.Subject has received any other investigational medicinal product (IMP) within 30 days
- •14.Subject has any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data including acute trauma to the pelvis or urinary tract
- •15. Subject is receiving vasopressor therapy at Screening
研究者
相似试验
进行中（未招募）
1 期
Study to assess the safety, tolerability and exposure of cefiderocol in children with suspected or confirmed aerobic Gram-negative bacterial infections.Including but not limited to complicated urinary tract infection [cUTI], complicated intra-abdominal infection [cIAI], hospital-acquired pneumonia [HAP]/ventilator-acquired pneumonia [VAP], and sepsis or bloodstream infections [BSI]MedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10076918Term: Hospital acquired pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10065153Term: Ventilator associated pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10079983Term: Complicated intra-abdominal infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10003997Term: BacteraemiaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10053840Term: Bacterial sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-002120-32-LVShionogi B.V.64
进行中（未招募）
不适用
An open label, single arm study to assess the safety and immunogenicity of omalizumab liquid administered subcutaneously in a pre-filled safety syringe (75 mg or 150 mg) over a period of 6 months to male and female adolescents and adults with moderate to severe persistent allergic asthmamoderate to severe persistent allergic asthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-005917-36-DEovartis Pharma Services AG100
进行中（未招募）
不适用
Safety and Tolerability of Cinacalcet in Pediatric Subjects With Chronic Kidney Disease and Secondary HyperparathyroidismSecondary hyperparathyroidism in pediatric subjects with chronic kidney disease receiving hemodialysis or peritoneal dialysisMedDRA version: 16.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2011-004618-40-DEAmgen Inc.20
进行中（未招募）
1 期
Safety and Tolerability of Cinacalcet in Pediatric Subjects With Chronic Kidney Disease and Secondary HyperparathyroidismSecondary hyperparathyroidism in pediatric subjects with chronic kidney disease receiving hemodialysis or peritoneal dialysisMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2011-004618-40-ITAmgen Inc.30
进行中（未招募）
1 期
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants with Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately-controlled SeizuresDravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut SyndromeMedDRA version: 20.0Level: LLTClassification code: 10073682Term: Dravet syndrome Class: 10010331MedDRA version: 21.0Level: PTClassification code: 10080584Term: Tuberous sclerosis complex Class: 100000004850MedDRA version: 20.1Level: PTClassification code: 10048816Term: Lennox-Gastaut syndrome Class: 100000004852CTIS2023-505851-33-00Gw Research Limited27